Ganeden Biotech and P.L. Thomas announced that PLT will expand their partnership to accelerate the expansion of Ganeden's proprietary and patented GanedenBC30 probiotic into the U.S. food and beverage industries. PLT will fully utilize its technical sales and marketing expertise in the food industry to complement the impressive debut GanedenBC30 has made in milk, ice cream, baked goods, teas and numerous items. The rigorous and costly regulatory approval process Ganeden has funded should encourage all potential clients to evaluate this safe, beneficial and robust probiotic.
Paul Flowerman, president of PLT, states: "On Aug. 2, 2012, the FDA issued a "No Objection Letter" in response to Ganeden's GRAS petition, which included a list of Ganeden's published clinical studies which support the conclusion that GanedenBC30 is safe and helps to support digestive and immune health. Ganeden has put in place a formidable business development system, which provides tremendous support to potential clients who wish to determine the efficacy and safety of utilizing GanedenBC30 to enhance their product offering.
PLT and Ganeden will provide appropriate prototypes and on-the-shelf comparable products. Client trial formulations will be tested at no charge for survival of the microbes and further support will be provided on the science and processing, including validated post-manufacturing cleanup. PLT will closely coordinate its promotion and sales activities with Ganeden, demonstrating that "the whole is much greater than the sum of its parts. PLT has recently strengthened its capabilities to partner with Ganeden with the hiring of a PhD microbiologist with specialization in probiotics and an MS nutrition/food scientist with probiotics experience. In addition, Dr. Barbara Davis, PhD Nutrition, will join PLT on Oct. 15 as director of scientific affairs, adding her extensive knowledge of probiotics, obtained during her tenure with Dannon, to the BC30 campaign," according to Mr. Flowerman.
Mike Bush, vice president of Ganeden Labs' sales and marketing, states, "We have had a long standing relationship with PL Thomas and we are pleased to see them redoubling their efforts to promote GanedenBC30 to the masses and expand into food applications that allow consumers to consume this beneficial probiotic in product formats they already enjoy every day."
GanedenBC30 is the first Bacillus strain to receive GRAS No FDA Objection status. It presents an unmatched ability to robustly survive many manufacturing processes, have a longer shelf life and survive stomach acids and intestinal bile. GanedenBC30 may be incorporated into a variety of foods ranging from frozen yogurt and baked goods to hot cereals and confections. The strength of GanedenBC30 can be linked to its naturally occurring layer of organic material that protects the genetic core of the bacteria. Other probiotics, such as Lactobacillus and Bifidobacterium, are unable to form this protective layer, making them more vulnerable to manufacturing conditions.
Food/Beverage industry clients will learn more about GanedenBC30 at SupplySide West (PLT booth #20025) and Engredea (PLT booth #354). To learn more about GanedenBC30, the research that supports it and its competitive advantages, contact PL Thomas at 973-984-0900 x219.